Skip to main content
. Author manuscript; available in PMC: 2022 Aug 4.
Published in final edited form as: Int J Cancer. 2022 Jul 19;151(11):1913–1924. doi: 10.1002/ijc.34202

Table 2.

Clinical presentation and outcomes of COVID-19 infection.

N=87

Clinical presentation, n(%)
Asymptomatic 26 (30)

Fever 38 (44)
Myalgia 16 (18)

URI 47 (54)
LRI 18 (21)

GI 25 (29)
Neurological 9 (10)

Cardiac 5 (6)
Skin 6 (7)
Hospitalization, n(%)
COVID related 26 (30)
 -Multiple hospitalizations 4
COVID unrelated 14 (16)
Not hospitalized 47 (54)
Severity *
Mild 69
Moderate 10
Severe 2
Critical 6
Hypoxia, n(%) 12 (14)
Intensive care, n (%) 6(7)
Invasive ventilation# 2
Organ failure 6
Any Treatment, n (%) 19 (22)
Remdesivir 14
Steroids 11
Monoclonal 2
Convalescent Plasma 4
Hydroxychloroquine 1
Azithromycin 2
Other 1
Therapy delay
(n=64 on active therapy)
Delayed 22
Duration of delay
(days, median (range))
14(2–39)@

URI: Upper respiratory infection, LRI: lower respiratory infection

*

Severity was graded using the World Health Organization scale. Mild: no pneumonia or hypoxia. Moderate: clinical signs of pneumonia, chest radiography may help in diagnosis. Severe: oxygen saturation <90% on room air or signs of severe respiratory distress (accessory muscle use, grunting.) Critical: life-sustaining treatment for conditions such as acute respiratory distress syndrome (ARDS), sepsis, or septic shock.

#

Intubation and ventilation.

@

radiotherapy was omitted in one patient due to COVID-19.